On June 10, 2025, Insmed announced positive results from its Phase 2b study of TPIP for pulmonary arterial hypertension, meeting all primary and secondary endpoints, including a 35% reduction in pulmonary vascular resistance. The study involved 102 patients and will lead to a Phase 3 trial beginning in 2026.